Gene
VEGFA
VEGFA is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (335), Actionable biomarkers (1), Trial mentions (3,062), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention VEGFA. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 8 with a planned future start and 7 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 257 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 166 of 8,738 | 1.90% | not measured | |
| 2025 | 174 of 8,875 | 1.96% | not measured | |
| 2024 | 167 of 8,597 | 1.94% | not measured | |
| 2023 | 152 of 8,275 | 1.84% | 510 of 11,460 | 4.45% |
| 2022 | 176 of 8,285 | 2.12% | 643 of 13,598 | 4.73% |
| 2021 | 182 of 8,692 | 2.09% | 782 of 15,045 | 5.20% |
| 2020 | 154 of 7,640 | 2.02% | 727 of 14,459 | 5.03% |
| 2019 | 141 of 7,300 | 1.93% | 568 of 12,159 | 4.67% |
| 2018 | 147 of 6,927 | 2.12% | 536 of 11,854 | 4.52% |
| 2017 | 140 of 6,558 | 2.13% | 508 of 11,595 | 4.38% |
Showing 10 of 37 years.
Assay-provider ledger (335)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Meso Scale Diagnostics | Reagent supplier | Clinical validationAnalytical validation | 4 | September 01, 2026 +1 undated |
| Luminex | Reagent supplier | Clinical validationAnalytical validation | 11 | August 01, 2026 +4 undated |
| R & D Systems | Reagent supplier | Clinical validationAnalytical validation | 58 | August 01, 2026 +15 undated |
| BIOCARE MEDICAL LLC | Reagent supplier | Clinical validation | 1 | July 16, 2026 |
| Leica BioSystems | Unclassified | Clinical validation | 2 | July 16, 2026 |
Showing 5 of 335 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| VEGFA amplification | Sorafenib | response-associated | hepatocellular carcinoma | Cancer Genome Interpreter |
Trial mentions (3,062)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03626233 | Trial biospecimen (AACT) |
| NCT05727982 | Trial biospecimen (AACT) |
| NCT02214511 | Trial biospecimen (AACT) |
| NCT00673517 | Trial biospecimen (AACT) |
| NCT05385913 | Trial biospecimen (AACT) |
Showing 5 of 3,062 trial mentions.
Target-disease associations (1,685)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Literature (Europe PMC) |
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 8p23.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 8q24.3 microdeletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
Showing 5 of 1,685 associations.
Vendor sourcing (9,318)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 1Globe Health Institute | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV) * Progression during or within 3 months following the last ... | View trial NCT03522649 |
| 1Globe Health Institute | Trial sponsor | Mentioned in trial textTrial free-text mention | VEGF | View trial NCT03522649 |
| 23andMe (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Part A: Adults ≥ 18 years of age; Part B: ≥ 12 to years of age, weighing at least 40 kg (total body weight) 2. Part A: Histologically-diagnosed locally... | View trial NCT05199272 |
| 23andMe (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | VEGF | View trial NCT05199272 |
| 3D Medicines, Inc. (China) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Previous lab results showed dMMR or MSI-H. 2. Participate in the clinical trials of other investigational drugs within 28 days before the first medicat... | View trial NCT05112991 |
Showing 5 of 9,318 sourcing records.
Trial-cited literature (8,661)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Current Status of Research on Losartan in Tumour Therapy. | Journal of cellular and molecular medicine | 2026 | 6 |
| Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial. | Ophthalmology | 2026 | 4 |
| Clinical and radiographic evaluation of autologous albumin-rich platelet-rich fibrin membrane versus synthetic collagen membrane for immediate dental implant placement in the maxillary esthetic zone: a preliminary randomized clinical trial. | BMC oral health | 2026 | 2 |
| Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer. | International journal of clinical oncology | 2026 | 2 |
| Adding blood flow restriction to isokinetic resistance training provides no additional benefit for strength, but may improve local muscular endurance: a randomized controlled trial. | BMC sports science, medicine & rehabilitation | 2026 | 1 |
Showing 5 of 8,661 papers.
Protein variant mentions (52)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C12D | 1 | 2022 | PMID 35365190 |
| p.C156S | 3 | 2003 to 2019 | PMID 30863410, PMID 30046111, PMID 12810700 |
| p.E0821111A | 1 | 2017 | PMID 28587096 |
| p.F001M | 1 | 2021 | PMID 33672081 |
| p.F002F | 1 | 2021 | PMID 33672081 |
Showing 5 of 52 variants.
Literature-extracted relations (2,645)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| BEVACIZUMAB | Chemical | negative_correlate |
Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer. | 2026 |
| NIVOLUMAB | Chemical | positive_correlate |
Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer. | 2026 |
| Lithium | Chemical | associate |
Lack of sustained improvements in erectile function following low-intensity extracorporeal shockwave therapy correlate with decreases in corporal brain-derived neurotropic factor: a pilot study and prospective clinical trial. | 2025 |
| BEVACIZUMAB | Chemical | negative_correlate |
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). | 2025 |
| Ranibizumab | Chemical | negative_correlate |
One-year results of visual response following intravitreal novel anti-VEGF injection for diabetic macular edema in a Latino population. | 2025 |
Showing 5 of 2,645 relation assertions.
Organizations publishing (2,076)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 221 | 1996 to 2024 |
| Harvard Medical School | Academic | 202 | 1996 to 2025 |
| The University of Texas System | Academic | 190 | 1995 to 2026 |
| Memorial Sloan Kettering Cancer Center | Hospital | 182 | 2006 to 2025 |
| Mass General Brigham | Hospital | 176 | 1996 to 2025 |
Showing 5 of 2,076 organizations.
Where VEGFA appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,513 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.